Literature DB >> 14639124

The in vitro effects of H-89, a specific inhibitor of protein kinase A, in the human colonic carcinoma cell line Caco-2.

S Böckmann1, B Nebe.   

Abstract

SUMMARY: H-89 is a compound characterized in vitro as a potent and selective inhibitor of protein kinase A. In the present study, we observed that H-89 induced morphological transformation and caused growth inhibition of the human colon cancer cell line Caco-2 in a dose-dependent manner. However, another protein kinase A inhibitor, H-8, had no effect on Caco-2 cells. To evaluate the possible molecular mechanism of H-89-evoked effects in Caco-2 cells, we analysed the capacity of H-89 to regulate the protein kinase B (Akt/PKB) signalling pathway. H-89 treatment led to an activation of Akt/PKB in Caco-2 cells. This activation was phosphatidylinositol 3 (PI3)-kinase-dependent and promoted survival of Caco-2 cells because the PI3 kinase inhibitor LY294002 inhibited the Akt/PKB activation and induced apoptosis of Caco-2 cells. To test whether Akt/PKB activity promoted resistance to H-89-induced effects, LY294002 was added in combination with H-89. LY294002 greatly potentiated the H-89-induced growth inhibition and apoptosis of Caco-2 cells. These results suggest that the H-89-induced growth inhibition of Caco-2 cells is associated with phosphorylation of Akt/PKB protein and that the cells become more sensitive to H-89 and die by apoptosis upon inhibition of the PI3K/Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639124     DOI: 10.1097/00008469-200312000-00005

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

1.  Response of chondrocytes to shear stress: antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1.

Authors:  Pu Wang; Fei Zhu; Ziqiu Tong; Konstantinos Konstantopoulos
Journal:  FASEB J       Date:  2011-06-29       Impact factor: 5.191

2.  Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.

Authors:  Priya Mahajan; Bhumika Wadhwa; Manas Ranjan Barik; Fayaz Malik; Amit Nargotra
Journal:  Mol Divers       Date:  2019-02-23       Impact factor: 2.943

Review 3.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

4.  Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors.

Authors:  Riccardo Zanni; Maria Galvez-Llompart; Cecilia Morell; Nieves Rodríguez-Henche; Inés Díaz-Laviada; Maria Carmen Recio-Iglesias; Ramon Garcia-Domenech; Jorge Galvez
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

5.  Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.

Authors:  Tak L Khong; Ngayu Thairu; Helene Larsen; Peter M Dawson; Serafim Kiriakidis; Ewa M Paleolog
Journal:  BMC Cancer       Date:  2013-11-02       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.